Clinical Trials Search Tool

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2 years of age and above

Enrollment Opens: 04-29-2022

Enrollment Closes: TBD


This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with AD. Subjects in this study will have either: a) completed treatment with tapinarof or vehicle in one of two Phase 3 pivotal safety and efficacy studies, DMVT-505-3101 or DMVT-505-3102, and rolled over into this study; b) completed treatment with tapinarof in the Phase 2 maximal use pharmacokinetics [PK] study, DMVT-505-2104, and rolled over into this study; or c) enrolled directly into this study.

Study ID: DMVT-505-3103

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 4 or visit us on the web at

Posted by: Cyn3rgy Research |